Biomarkers of bone turnover in diagnosis and therapy of osteoporosis
详细信息 查看全文
- 作者：Univ.-Prof. Christian Bieglmayer Ph.D. (1) (2)
Univ.-Prof. Hans Peter Dimai M.D. (3)
Univ.-Prof. Rudolf Wolfgang Gasser M.D. (4)
Univ.-Doz. Stefan Kudlacek M.D. (5)
Univ.-Prof. Barbara Obermayer-Pietsch M.D. (6)
Univ.-Prof. Wolfgang Woloszczuk Ph.D. (7)
Elisabeth Zwettler M.D. (8)
Univ.-Prof. Andrea Griesmacher M.D. (9) - 关键词：Advice ; Biomarkers ; Bone turnover ; Osteoporosis ; Leitfaden ; Biomarker ; Knochenumbau ; Osteoporose
- 刊名：Wiener Medizinische Wochenschrift
- 出版年：2012
- 出版时间：November 2012
- 年：2012
- 卷：162
- 期：21-22
- 页码：464-477
- 全文大小：1295KB
- 参考文献：1. Seibel MJ. Biochemical markers of bone remodelling. Endocrinol Metab Clin North Am. 2003;32:83鈥?13. CrossRef
2. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11(Suppl 6):S2鈥?7. CrossRef
3. WHO Technical report series鈥攁ssessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994.
4. Kanis J, Melton L, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137鈥?1. CrossRef
5. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(Suppl 2):S3鈥?. CrossRef
6. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285鈥?. CrossRef
7. Cooper C, Cole ZA, Holroyd CR, et al. and IOF CSA Working Group on Fracture Epidemiology. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277鈥?8. CrossRef
8. Dimai HP, Svedbom A, Fahrleitner-Pammer A, et al. Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int. 2011;22:685鈥?2. CrossRef
9. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556鈥?1. CrossRef
10. Kanis JA, Borgstrom F, De Laet C, Johansson H, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581鈥?. CrossRef
11. Kanis JA, Johnell O, Oden A, et al. FRAX鈩?and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385鈥?7. CrossRef
12. Anderson F, Francis R, Selby P, et al. Sex hormones and osteoporosis in men. Calcif Tissue Int. 1998;68:185鈥?. CrossRef
13. Ludwig H, Fritz E, Friedl H. Epidemiologic and age dependent data on multiple myeloma in Austria. J Nat Cancer Inst. 1982;68:729鈥?3.
14. McFarlane X, Bhalla A, Reeves D, et al. Osteoporosis in treated adult coeliac disease. Gut. 1995;36:710鈥?. CrossRef
15. Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008;19:1683鈥?04. CrossRef
16. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11:1鈥?31.
17. Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007;30:171鈥?4. CrossRef
18. Christiansen C, Baastrup PC, Transbol I. Osteopenia and dysregulation of divalent cations in lithium-treated patients. Neuropsychobiology. 1975;1:344鈥?4. CrossRef
19. Zamani A, Omrani GR, Nasab MM. Lithium鈥檚 effect on bone mineral density. Bone. 2009;44:331鈥?. CrossRef
20. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319鈥?6. CrossRef
21. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32鈥?. CrossRef
22. Jamal SA, Browner WS, Bauer DC, et al. Warfarin use and risk for osteoporosis in elderly women. Study of osteoporotic fractures research group. Ann Intern Med. 1998;128:829鈥?32.
23. Rezaieyazdi Z, Falsoleiman H, Khajehdaluee M, et al. Reduced bone density in patients on long term warfarin. Int J Rheum Dis. 2009;12:130鈥? CrossRef
24. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1117鈥?1.
25. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteoporosis and osteopenia. Bone. 2000;27:585鈥?0. CrossRef
26. Cummings S, Black D, Nevitt M. for the study of osteoporotic fractures research group. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341,72鈥?. CrossRef
27. Cooper C, Atkinson E, Jacobsen S, et al. Population based study of survival following osteoporotic fractures. Am J Epidemiol. 1993;137:1001鈥?.
28. Kudlacek S, Schneider B, Resch H, et al. Die lumbale BMD 鈥?Risikofaktor f眉r Wirbelk枚rperfrakturen bei der Frau. Dtsch Med Wschr. 1998;123:651鈥?. CrossRef
29. Dobnig H. A review of the health consequences of the vitamin D deficiency pandemic. J Neurol Sci. 2011 Sept 21. Epub ahead of print.
30. Sahota O, Mundey MK, San P, et al. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone. 2004;35:312鈥?. CrossRef
31. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84:18鈥?8.
32. Kudlacek S, Schneider B, Peterlik M, et al. And Austrian study group on normative values of bone metabolism. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest. 2003;33:323鈥?1. CrossRef
33. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116:634鈥?. CrossRef
34. Garnero P, Munoz F, Sornay-Rendu E, et al. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40:716鈥?2. CrossRef
35. Meier C, Woitge HW, Witte K, et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res. 2004;19:1221鈥?0. CrossRef
36. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257鈥?4. CrossRef
37. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. and Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911鈥?0. CrossRef
38. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res. 1996;11:1531鈥?. CrossRef
39. Garnero P, Sornay-Rendu E, Duboeuf F, et al. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;14:1614鈥?1. CrossRef
40. Garnero P, Sornay-Rendu E, Claustrat B et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women. The OFELY study. J Bone Min Res. 2000;15:1526鈥?6. CrossRef
41. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact. 2004;4:50鈥?3.
42. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367:284鈥?. CrossRef
43. Obermayer-Pietsch BM, Bonelli CM, Walter DE, et al. Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures. J Bone Miner Res. 2004;19:42鈥?. CrossRef
44. Gugatschka M, Dobnig H, Fahrleitner-Pammer A, et al. Molecularly defined lactose malabsorption, milk consumption and anthropometric differences in adult males. Quart J Med. 2005;12:857鈥?3. CrossRef
45. Ji GR, Yao M, Sun CY, et al. Association of collagen type I alpha1 (COLIA1) Sp1 polymorphism with osteoporotic fracture in Caucasian post-menopausal women: a meta-analysis. J Int Med Res. 2009;37:1725鈥?2.
46. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337鈥?9. CrossRef
47. Srivastava AK Vilet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21:1015鈥?6. CrossRef
48. Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29鈥?7. CrossRef
49. Delmas PD. The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women. Osteoporosis Int. 1998;8(Suppl 1):S32鈥?. CrossRef
50. van Daele PL, Seibel MJ, Burger H, et al. Case-control-analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. Brit Med J. 1996;312:482鈥?. CrossRef
51. Pfeilschifter J, Kann PH. Diagnostik der Osteoporose. Z Gastroenterol. 2002;40:46鈥?6. CrossRef
52. Stepan JJ. Clinical value of the biochemical markers of bone remodelling in the assessment of bone metabolic diseases. Jugoslov Med Biohem. 2006;25:241鈥?. CrossRef
53. Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture Intervention trial. J Bone Miner Res. 2006;21:292鈥?. CrossRef
54. Kreihuber A. Osteoporosetherapie 鈥?aktueller Daten眉berblick zu Raloxifen. J Miner Stoffwechs. 2008;15:220鈥?.
55. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002;162:1140鈥?. CrossRef
56. Cummings SR, San Martin J, McClung MR, et al. the FREEDOM trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756鈥?5. CrossRef
57. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1鈥?4) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932鈥?1. CrossRef
58. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1鈥?4) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434鈥?1. CrossRef
59. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459鈥?8. CrossRef
60. Christgau S, Cloos PA. Current and future applications of bone turnover markers. Clin Lab. 2003;49:439鈥?6.
61. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85:3109鈥?5 CrossRef
62. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586鈥?2. CrossRef
63. Bergmann P, Body JJ, Boonen S, et al. and Members of Advisory Board on Bone Markers. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19鈥?6. CrossRef
64. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrin Metab. 2006;91:1370鈥?. CrossRef
65. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005;90:3970鈥?. CrossRef
66. Black DM, Greenspan SL, Ensrud KE, et al. and PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207鈥?5. CrossRef
67. H, Cosman F, Endres DB, et al. Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; Approved Guideline. In: NCCLS document C48-A (ISBN 1-56238-539-9) 2004; 24 (22). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087鈥?898 USA.
68. Bieglmayer C, Clodi M, Kudlacek S. Biomarker in der Osteologie: Aktueller Stand. J Miner Stoffwechs. 2006;13:82鈥?.
69. Ganero P. Markers of bone turnover in prostate cancer. Cancer Treatm Rev. 2001;27:187鈥?2. CrossRef
70. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. In J Ca. 2004;111:783鈥?1.
71. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Brit J Ca. 2003;89:2031鈥?7. CrossRef
72. de la Piedra C, Castro-Errecaborde NA, Traba ML, et al. Bone remodelling markers in the detection of bone metastases in prostate cancer. Clin Chem Acta. 2003;331:45鈥?3 CrossRef
73. Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer. 2003;10:21鈥?. CrossRef
74. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503鈥?3. CrossRef
75. Beke D, Kudlacek S, Meran JG. Klinische Relevanz von Biomarkern bei der Skelettmetastasierung von Malignomen. Wien Med Wochenschr. 2007;157:375鈥?0. CrossRef
76. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193鈥?01. CrossRef
77. Lipton A, Chapman JA, Demers L, et al. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol. 2011;29:3605鈥?0. CrossRef
78. Naylor KE, Iqbal P, Fledelius C, et al. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000;15:129鈥?7. CrossRef
79. Woitge HW, Friedmann B, Suttner S, et al. Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res. 1998;13:1797鈥?804. CrossRef
80. Ma茂moun L, Manetta J, Couret I, et al. The intensity level of physical exercise and the bone metabolism response. Int J Sports Med. 2006;27:105鈥?11. CrossRef
81. Huber F, Traber L, Roth HJ, et al. Markers of bone resorption鈥攎easurement in serum, plasma or urine? Clin Lab. 2003;49:203鈥?.
82. Schmidt-Gayk H, Huber F, Traber L, et al. Vitamin-D-Versorgung und Marker des Knochenabbaus (b-CrossLaps) bei pr盲- und postmenopausalen Frauen. Osteoporose Rheuma aktuell. 2003;4:36鈥?2.
83. Garnero P, Mulleman D, Munoz F, et al. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res. 2003;18:1789鈥?4. CrossRef
84. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 2000;26:505鈥?1. CrossRef
85. Bjarnason NH, Henriksen EEG, Alexandersen P, et al. Mechanism of circadian variation in bone resorption. Bone. 2002;30:307鈥?3. CrossRef
86. Schmidt-Gayk H, Roth HJ, Becker S, et al. Noninvasive parameters of bone metabolism. Curr Opin Nephrol Hypertens. 1995 Jul;4:334鈥?. CrossRef
87. Ohishi T, Takahashi M, Kushida K, et al. Changes of biochemical markers during fracture healing. Arch Orthop Trauma Surg. 1998;118:126鈥?0. CrossRef
88. Ingle BM, Hay SM, Bottjer HM, et al. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos Int. 1999;10:399鈥?07. CrossRef
89. Akesson K, K盲k枚nen SM, Josefsson PO, et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab. 2005;23:30鈥?. CrossRef
90. Veitch SW, Findlay SC, Hamer AJ, et al. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int. 2006;17:364鈥?2. CrossRef
91. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993;77:1046鈥?3. CrossRef
92. Alvarez L, Gua帽abens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget鈥檚 disease. Bone 2001;29:447鈥?2. CrossRef
93. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996;42:947鈥?4.
94. Bornstein P. The NH. (2)-terminal propeptides of fibrillar collagens: highly conserved domains with poorly understood functions. Matrix Biol. 2002;21:217鈥?6. CrossRef
95. Tahtela R, Seppanen J, Laitinen K, et al. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int. 2005;16:1109鈥?6. CrossRef
96. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962鈥?0. CrossRef
97. Schytte S, Hansen M, Moller S, et al. Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest. 1999;59:627鈥?4. CrossRef
98. Hellman J, Kakonen SM, Matikainen MT, et al. Epitope mapping of nine monoclonal antibodies against osteocalcin: combinations into two-site assays affect both assay specificity and sample stability. J Bone Miner Res. 1996;11:1165鈥?5. CrossRef
99. Takahashi M, Kushida K, Nagano A, et al. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta. 2000;294:67鈥?6. CrossRef
100. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Ann Clin Biochem. 1995;32:422鈥?.
101. Noonan K, Kalu ME, Holownia P, et al. Effect of different storage temperatures, sample collection procedures and immunoassay methods on osteocalcin measurement. Eur J Clin Chem Clin Biochem. 1996;34:841鈥?.
102. Colford J, Sailer D, Langman C. Five osteocalcin assays compared: tracer specificity, fragment interference, and calibration. Clin Chem. 1997;43:1240鈥?.
103. Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 1997;82:719鈥?4. CrossRef
104. Holzer G, Grasse AV, Zehetmayer S, et al. Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: a pilot study. Transl Res. 2010;156:37鈥?4. CrossRef
105. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456鈥?9. CrossRef
106. Fern谩ndez-Real JM, Izquierdo M, Ortega F, et al. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab. 2009;94:237鈥?5. CrossRef
107. Iki M, Tamaki J, Fujita Y, et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo osteoporosis risk in men (FORMEN) Study. Osteoporos Int. 2011 Mar 25. Epub ahead of print.
108. Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab. 1995;80:864鈥?. CrossRef
109. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products from type I collagen C-telopetides. Clin Chem. 1998;44:2290鈥?00.
110. Ganero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47:694鈥?02.
111. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of Ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527鈥?3. CrossRef
112. Delmas PD, Adami S, Strugula C, et al. Intravenous Ibandronate Injections in postmenopausal women with osteoporosis. Arthritis Rheum. 2006;54:1838鈥?6. CrossRef
113. Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654鈥?1. CrossRef
114. Halleen JM, Raisanen S, Salo JJ, et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem. 1999;274:22907鈥?0. CrossRef
115. Janckila AJ, Nakasato YR, Neustadt DH, et al. Disease-specific expression of tartrate-resistant acid phosphatase isoforms. J Bone Miner Res. 2003;18:1916鈥?. CrossRef
116. Halleen JM, Alatalo SL, Janckila AJ, et al. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem. 2001;47:597鈥?00.
117. Hannon RA, Clowes JA, Eagleton AC, et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187鈥?4. CrossRef
118. 103 K/DOQI guidelines for the management of renal osteodystrophy. Am J Kidney Dis. 2003;42(Suppl 3):S1鈥?01.
119. Souberbielle J-C, Boutten A, Carlier M-C, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345鈥?0. CrossRef
120. Woitge HW, Knothe A, Witte K, et al. Circannual rhythmus and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. JBMR. 2000;15:2443鈥?0. CrossRef
121. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteporos Int. 2010;21:1151鈥?. CrossRef
122. Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53鈥?. CrossRef - 作者单位：Univ.-Prof. Christian Bieglmayer Ph.D. (1) (2)
Univ.-Prof. Hans Peter Dimai M.D. (3)
Univ.-Prof. Rudolf Wolfgang Gasser M.D. (4)
Univ.-Doz. Stefan Kudlacek M.D. (5)
Univ.-Prof. Barbara Obermayer-Pietsch M.D. (6)
Univ.-Prof. Wolfgang Woloszczuk Ph.D. (7)
Elisabeth Zwettler M.D. (8)
Univ.-Prof. Andrea Griesmacher M.D. (9)
1. 脰QUASTA (Austrian Society for Quality Assurance and Standardization of Medical Laboratory Tests), 1090 H枚rlgasse 18/5, Vienna, Austria
2. Department of Laboratory Medicine Diagnostics, General Hospital of Vienna, Medical University of Vienna, 1090 W盲hringer G眉rtel 18-20, Vienna, Austria
3. Department of Endocrinology and Metabolism, Clinic for Internal Medicine, Medical University of Graz, Graz, Austria
4. Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria
5. Internal Medicine, Hospital of Brothers of Charity (Krankenhaus der Barmherzigen Br眉der), Vienna, Austria
6. Laboratory for Endocrinology and Metabolism, Clinic for Internal Medicine Medical University of Graz, Graz, Austria
7. Biomarker Design Forschungs GmbH, Vienna, Austria
8. Ludwig Boltzmann Institute of Osteology, 1st Medical Department, Hanusch Hospital WGKK and AUVA Trauma Center Meidling, Vienna, Austria
9. Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria - ISSN：1563-258X
文摘